Can Yeast Be The Future Of Large Scale And Efficient Subunit Vaccine Manufacturing?
By Lisa Yu and Devarshi Kapadia

Vaccines have been developed at record breaking speeds to fight the COVID-19 pandemic and are already saving lives1. At the time of writing, over 2.55 billion COVID-19 vaccine2 doses have been administered globally and are paving the way to a return to a "new normal." However, there is still a pressing need to develop more vaccine options to further increase global access, and prepare for future infectious disease challenges. To aid in the manufacturing of new vaccines, Pichia pastoris yeast, a promising protein expression system, could be the perfect solution.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
This website uses cookies to ensure you get the best experience on our website. Learn more